Tsuchiya Y, Tamura H, Fujii K, Numaguchi H, et al. Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan. Vaccine 2023 Jan 5:S0264-410X(23)00006-3. doi: 10.1016/j.vaccine.2023.
PMID: 36732164